# A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Source: https://onco.cc/trials/nct07227402/  
OnCo record `nct07227402` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Zanzalintinib in renal cell carcinoma, now recruiting.

## Summary

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) is a phase 3 interventional study registered as NCT07227402, led by Merck Sharp & Dohme with Exelixis, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033). Planned enrolment is 904 participants (estimated). The study started in 2025-11-26 and primary completion is expected in 2032-02-27. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: LITESPARK-033
- Tags: ctgov-ingest
- Registry id: NCT07227402
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
- Sponsor: Merck Sharp & Dohme
- Enrolled: 904

## Sources

- ClinicalTrials.gov NCT07227402: https://clinicaltrials.gov/study/NCT07227402

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Zanzalintinib](https://onco.cc/drugs/zanzalintinib/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07227402.json